Literature DB >> 15885866

Estimation of private and social time preferences for health in northern Tanzania.

Bjarne Robberstad1.   

Abstract

Time preferences for health has a role in informing discounting practice in economic evaluation of health care interventions. Yet virtually no empirical evidence on time preferences for health are available for sub-Saharan Africa. The objectives of this paper are therefore to estimate time preferences for health in Tanzania, and to explore the relationship between time preferences for one's own private health and for others health. Determinants of time preference rates are also explored. A sample of the general population participated, and each person was asked to indicate the maximum duration of more distant ill-health they would be willing to accept in return for a specified delay in the onset of the condition. People were randomised to answer either questions in the context of their own health or in the context of others health. Estimations were done using clustered least squares regression with robust standard errors. The implied mean and median discount rates were 0.07 and 0.058, respectively. Time preferences for one's own and others' health--conceptualised as social health--seem to be roughly the same in this sample, but people seem to discount the most severe health condition at a significantly lower rate than the least severe condition.

Entities:  

Mesh:

Year:  2005        PMID: 15885866     DOI: 10.1016/j.socscimed.2005.03.013

Source DB:  PubMed          Journal:  Soc Sci Med        ISSN: 0277-9536            Impact factor:   4.634


  9 in total

1.  Time preferences for health in northern Tanzania: an empirical analysis of alternative discounting models.

Authors:  Bjarne Robberstad; John Cairns
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

2.  Cost-effectiveness of skin-barrier-enhancing emollients among preterm infants in Bangladesh.

Authors:  Amnesty LeFevre; Samuel D Shillcutt; Samir K Saha; A S M Nawshad Uddin Ahmed; Saifuddin Ahmed; Mak Azad Chowdhury; Paul A Law; Robert Black; Mathuram Santosham; Gary L Darmstadt
Journal:  Bull World Health Organ       Date:  2010-01-08       Impact factor: 9.408

3.  Cost-effectiveness of different interferon beta products for relapsing-remitting and secondary progressive multiple sclerosis: Decision analysis based on long-term clinical data and switchable treatments.

Authors:  Shekoufeh Nikfar; Abbas Kebriaeezadeh; Rassoul Dinarvand; Mohammad Abdollahi; Mohammad-Ali Sahraian; David Henry; Ali Akbari Sari
Journal:  Daru       Date:  2013-06-22       Impact factor: 3.117

4.  A Cost-Utility and Cost-Effectiveness Analysis of Different Oral Antiviral Medications in Patients With HBeAg-Negative Chronic Hepatitis B in Iran: An Economic Microsimulation Decision Model.

Authors:  Khosro Keshavarz; Abbas Kebriaeezadeh; Seyed Moayed Alavian; Ali Akbari Sari; Mohsen Rezaei Hemami; Farhad Lotfi; Amir Hashemi Meshkini; Mehdi Javanbakht; Maryam Keshvari; Shekoufeh Nikfar
Journal:  Hepat Mon       Date:  2016-08-14       Impact factor: 0.660

5.  A Cost-Utility Analysis of Different Antiviral Medicine Regimens in Patients With Chronic Hepatitis C Virus Genotype 1 Infection.

Authors:  Seyed Moayed Alavian; Shekoufeh Nikfar; Abbas Kebriaeezadeh; Farhad Lotfi; Ehsan Sanati; Mohsen Rezaei Hemami; Khosro Keshavarz
Journal:  Iran Red Crescent Med J       Date:  2016-10-02       Impact factor: 0.611

6.  Setting priorities for the health care sector in Zimbabwe using cost-effectiveness analysis and estimates of the burden of disease.

Authors:  Kristian Schultz Hansen; Glyn Chapman
Journal:  Cost Eff Resour Alloc       Date:  2008-07-28

Review 7.  Discounting in Economic Evaluations.

Authors:  Arthur E Attema; Werner B F Brouwer; Karl Claxton
Journal:  Pharmacoeconomics       Date:  2018-07       Impact factor: 4.981

8.  Private and social time preference for health outcomes: A general population survey in Iran.

Authors:  Alireza Mahboub-Ahari; Abolghasem Pourreza; Ali Akbari Sari; Trevor A Sheldon; Maryam Moeeni
Journal:  PLoS One       Date:  2019-02-01       Impact factor: 3.240

9.  Cost-Effectiveness Analysis of Biopharmaceuticals for Treating Rheumatoid Arthritis: Infliximab, Adalimumab, and Etanercept.

Authors:  Ahmad Gholami; Jassem Azizpoor; Elham Aflaki; Mehdi Rezaee; Khosro Keshavarz
Journal:  Biomed Res Int       Date:  2021-11-28       Impact factor: 3.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.